MX2009009424A - Derivados de 3-ciano-4-(4-tetrahidropiran-fenil)-piridin-2-ona. - Google Patents

Derivados de 3-ciano-4-(4-tetrahidropiran-fenil)-piridin-2-ona.

Info

Publication number
MX2009009424A
MX2009009424A MX2009009424A MX2009009424A MX2009009424A MX 2009009424 A MX2009009424 A MX 2009009424A MX 2009009424 A MX2009009424 A MX 2009009424A MX 2009009424 A MX2009009424 A MX 2009009424A MX 2009009424 A MX2009009424 A MX 2009009424A
Authority
MX
Mexico
Prior art keywords
compounds
diseases
mglur2
involved
prevention
Prior art date
Application number
MX2009009424A
Other languages
English (en)
Inventor
Jose Maria Cid-Nunez
Guillaume Albert Jacques Duvey
Andres Avelino Trabanco-Suarez
Gregor James Macdonald
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2007/052442 external-priority patent/WO2007104783A2/en
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Publication of MX2009009424A publication Critical patent/MX2009009424A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se relaciona con nuevos compuestos, en particular, nuevos derivados de piridinona de acuerdo con la fórmula (1), que incluyen cualquiera de sus formas estereoquímicamente isoméricas, o un solvato o una sal farmacéuticamente aceptable de los compuestos, en donde todos los radicales se definen en la solicitud y en las reivindicaciones. Los compuestos de acuerdo con la invención son moduladores alostéricos positivos de receptores de glutamato metabotrópicos subtipo 2 ("mGluR2"), útiles para el tratamiento o la prevención de trastornos neurológicos y psiquiátricos asociados con la disfunción de glutamato y enfermedades en las cuales participa el subtipo mGluR2 de receptores metabotrópicos. En particular, dichas enfermedades son trastornos del sistema nervioso central seleccionados del grupo de ansiedad, esquizofrenia, migraña, depresión y epilepsia. La invención, asimismo, se relaciona con composiciones farmacéuticas y procesos para la preparación de tales compuestos y tales composiciones, así como con el uso de estos compuestos para la prevención y el tratamiento de las enfermedades en las cuales participa mGluR2.
MX2009009424A 2007-03-07 2008-03-07 Derivados de 3-ciano-4-(4-tetrahidropiran-fenil)-piridin-2-ona. MX2009009424A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07103654 2007-03-07
PCT/EP2007/052442 WO2007104783A2 (en) 2006-03-15 2007-03-15 1,4 -di substituted 3-cyano-pyridone derivatives and their use as positive mglur2-recept0r modulators
EP07116403 2007-09-14
PCT/EP2008/052768 WO2008107481A1 (en) 2007-03-07 2008-03-07 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives

Publications (1)

Publication Number Publication Date
MX2009009424A true MX2009009424A (es) 2010-02-09

Family

ID=39431145

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009424A MX2009009424A (es) 2007-03-07 2008-03-07 Derivados de 3-ciano-4-(4-tetrahidropiran-fenil)-piridin-2-ona.

Country Status (18)

Country Link
US (1) US8906939B2 (es)
EP (1) EP2134708B1 (es)
JP (1) JP5357061B2 (es)
KR (1) KR20090125814A (es)
CN (1) CN101711244B (es)
AR (1) AR065654A1 (es)
AT (1) ATE509020T1 (es)
AU (1) AU2008223796B2 (es)
BR (1) BRPI0808509A2 (es)
CA (1) CA2680104C (es)
DK (1) DK2134708T3 (es)
EA (1) EA017294B1 (es)
IL (1) IL200329A0 (es)
MX (1) MX2009009424A (es)
NZ (1) NZ579988A (es)
PL (1) PL2134708T3 (es)
TW (1) TW200845978A (es)
WO (1) WO2008107481A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200900391A (en) * 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
CN101657430B (zh) 2007-03-15 2013-05-01 诺瓦提斯公司 有机化合物及其用途
MX2010002537A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-fenil-1h-piridin-2-onas 1,3-disubstituidas.
ES2365966T3 (es) 2007-09-14 2011-10-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disustituidas.
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP2012504595A (ja) * 2008-10-02 2012-02-23 ファイザー・インク Ａｍｐａ増強剤としてのオキソピペリジニルおよびピラニルスルホンアミド
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
AR076859A1 (es) 2009-05-12 2011-07-13 Ortho Mcneil Janssen Pharm Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011011964A (es) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-***并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
MD20150122A2 (ro) 2013-06-27 2016-05-31 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
PT3096790T (pt) 2014-01-21 2019-10-15 Janssen Pharmaceutica Nv Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso
CN105153027A (zh) * 2015-07-21 2015-12-16 东华大学 一种3-氰基-4-羟基-2-吡啶酮类化合物及其制备和应用

Family Cites Families (440)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790440A (es) 1971-10-23 1973-04-24 Bayer Ag
JPS50106981U (es) 1974-02-08 1975-09-02
US3906953A (en) 1974-05-23 1975-09-23 American Optical Corp Endoscopic surgical laser system
SU509578A1 (ru) 1974-09-19 1976-04-05 Стерлитамакский Химический Завод Способ получени пропилендиаминов
IE43079B1 (en) 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
GB1502312A (en) 1975-03-20 1978-03-01 Ici Ltd Quinolone derivatives
FR2311776A1 (fr) 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
JPS5382783U (es) 1976-12-13 1978-07-08
JPS5752334Y2 (es) 1977-03-16 1982-11-13
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DE2750288A1 (de) 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4432979A (en) 1981-10-26 1984-02-21 William H. Rorer, Inc. Pyridone compounds
FI824314L (fi) 1981-12-16 1983-06-17 Sankyo Co Thienopyrimidin-derivater, deras framstaellning och deras medicinska anvaendning
US4358453A (en) 1982-01-08 1982-11-09 Schering Corporation 1,2,4-Triazolo[4,3-a]pyridines
US4520025A (en) 1982-07-21 1985-05-28 William H. Rorer, Inc. Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
DE3406329A1 (de) 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
US4550166A (en) 1984-05-21 1985-10-29 American Cyanamid Company (Pyridinyl)-1,2,4-triazolo[4,3-a]pyridines
US5175157A (en) 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3717561A1 (de) 1987-05-25 1988-12-08 Thomae Gmbh Dr K Indol-, isochinolin- und benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4866074A (en) 1987-05-08 1989-09-12 Rorer Pharmaceutical Corporation Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same, and their uses
EP0308020A3 (en) 1987-09-18 1990-12-05 Merck & Co. Inc. 5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
US5260293A (en) 1988-01-30 1993-11-09 Merck Sharp & Dohme Limited Pyrazines, pyrimidines and pyridazines useful in the treatment of senile dementia
GB8804448D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
JP2614081B2 (ja) 1988-05-27 1997-05-28 大塚化学株式会社 光学活性β−ラクタム誘導体の製造法
DE68923527D1 (de) 1988-10-20 1995-08-24 Sandoz Ag Faserreaktive Azofarbstoffe.
US5032602A (en) 1988-12-14 1991-07-16 Bayer Aktiengesellschaft Inhibiting HMG-CoA reductase with novel substituted 2-pyridones and pyrid-2-thiones
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5280026A (en) 1989-05-30 1994-01-18 Smithkline Beecham Intercredit B.V. Thienopyrimidines
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
US4978663A (en) 1989-08-16 1990-12-18 Hoechst-Roussel Pharmaceuticals Inc. 5-(1-aminocyclohexyl)-2(1H)-pyridinone compounds which have pharmaceutical utility
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
DE3940480A1 (de) 1989-12-07 1991-06-13 Bayer Ag Chromogene enaminverbindungen, ihre herstellung und verwendung als farbbildner
AU6979091A (en) 1989-12-22 1991-07-24 Upjohn Company, The Pyridinones useful as antiatherosclerotic agents
FR2657610A1 (fr) 1990-01-29 1991-08-02 Rhone Poulenc Agrochimie Triazolopyridines herbicides.
GB9104238D0 (en) 1990-03-16 1991-04-17 Ici Pharma 3-tetrazolylthiomethyl cephalosporin antibiotics
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
EP0452002A3 (en) 1990-03-30 1992-02-26 Dowelanco Thienopyrimidine derivatives
RU1796625C (ru) 1990-06-27 1993-02-23 Киевский Государственный Университет Им.Т.Г.Шевченко 3-Амино-7-нитро-4(2,3,4-триметоксифенил)-2-фенил-1(2Н)изохинолон, обладающий аналептическим действием
DE69131268T2 (de) 1990-09-21 1999-12-30 Rohm & Haas Dihydropyridazinone und Pyridazinone als Fungizide
AU1532492A (en) 1991-04-18 1992-11-17 Dr. Lo Zambeletti S.P.A. Use of heterocyclic compounds for the treatment of inflammatory pain
DE4122240A1 (de) 1991-07-05 1993-01-07 Boehringer Mannheim Gmbh Dibenz(b,e)azepinderivate und diese enthaltende arzneimittel
DE4129340A1 (de) 1991-09-04 1993-03-11 Merck Patent Gmbh 1,2-dihydro-2-oxopyridine
US5332750A (en) 1991-09-04 1994-07-26 Merck Patent Gesellschaft Mit Beschrankter Haftung 1,2-dihydro-2-oxopyridines
DE4131924A1 (de) 1991-09-25 1993-07-08 Hoechst Ag Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5204198A (en) 1991-10-28 1993-04-20 Eastman Kodak Company Photoelectrographic elements utilizing nonionic sulfonic acid photogenerators
US5416099A (en) 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
DE4221583A1 (de) 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
JP2878531B2 (ja) 1991-12-16 1999-04-05 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
US5378720A (en) 1991-12-19 1995-01-03 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
AU668694B2 (en) 1991-12-19 1996-05-16 Sanofi-Synthelabo Saccharin derivative proteolytic enzyme inhibitors
TW219935B (es) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
GB9200293D0 (en) 1992-01-08 1992-02-26 Wyeth John & Brother Ltd Piperazine derivatives
GB9201694D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JP3042156B2 (ja) 1992-02-20 2000-05-15 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
DE4206045A1 (de) 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl substituierte pyridone
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
AU660132B2 (en) 1992-12-21 1995-06-08 Bayer Aktiengesellschaft Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
SE9300657D0 (sv) 1993-02-26 1993-02-26 Astra Ab New compounds
US5814645A (en) 1993-03-24 1998-09-29 Bayer Aktiengesellschaft Arylor hetaryl substituted nitrogen heterocycles and their use as pesticides
DE4316077A1 (de) 1993-05-13 1994-11-17 Bayer Ag Substituierte Mono- und Bihydridylmethylpyridone
JPH08511538A (ja) 1993-06-09 1996-12-03 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノゲン拮抗物質
DE4326758A1 (de) 1993-08-10 1995-02-16 Basf Ag [1,3,4]Triazolo[1,5-a]pyridine
US5824682A (en) 1993-08-18 1998-10-20 Janssen Pharmaceutica, N.V. Vasoconstrictive dihydrobenzopyran derivatives
CZ39396A3 (en) 1993-08-19 1996-05-15 Janssen Pharmaceutica Nv The use of substituted aryloxyalkyldiamines, the compounds per se, process of their preparation, pharmaceutical compositions based thereon and process of their preparation
WO1995006032A1 (en) 1993-08-20 1995-03-02 Banyu Pharmaceutical Co., Ltd. Tyrosine kinase inhibitor
US5424435A (en) 1993-10-18 1995-06-13 Olin Corporation 1-hydroxy-6-substituted-2-pyridones
US5500420A (en) 1993-12-20 1996-03-19 Cornell Research Foundation, Inc. Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
ES2160156T3 (es) 1994-03-10 2001-11-01 Fujisawa Pharmaceutical Co Derivados de naftaleno como agonistas de la prostaglandina i2.
ES2079323B1 (es) 1994-06-21 1996-10-16 Vita Invest Sa Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes.
GB9416554D0 (en) 1994-08-19 1994-10-12 Ciba Geigy Ag Glutamate receptor
CA2198242A1 (en) 1994-08-24 1996-02-29 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists
US5473077A (en) 1994-11-14 1995-12-05 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor agonists
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
US5512576A (en) 1994-12-02 1996-04-30 Sterling Winthrop Inc. 2-substituted 1,2,5,-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
DE19507522C2 (de) 1995-03-03 2003-05-28 Basf Ag Verfahren zur Herstellung von 3,4-Dihydroisochinolinverbindungen und 3,4-Dihydroisochinolinium-Salzen
US5869428A (en) 1995-03-13 1999-02-09 Ishihara Sangyo Kaisha Ltd. Pyridonesulfonylurea compounds, process for their production and herbicides containing them
DE19510965A1 (de) 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
KR100400639B1 (ko) 1995-04-27 2003-12-31 미쯔비시 웰 파마 가부시키가이샤 복소환식아미드화합물및그의의약용도
JPH08325248A (ja) 1995-05-26 1996-12-10 Chugoku Kayaku Kk テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法
US5849587A (en) 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
US5659033A (en) 1995-09-13 1997-08-19 Neurogen Corporation N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
WO1997010238A1 (fr) 1995-09-15 1997-03-20 Synthelabo Derives de quinolein-2(1h)-one comme antagonistes de la serotonine
JPH1045750A (ja) 1995-09-20 1998-02-17 Takeda Chem Ind Ltd アゾール化合物、その製造方法及び用途
US6130217A (en) 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EA000710B1 (ru) 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
US6084084A (en) 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
US5710274A (en) 1996-02-28 1998-01-20 Neurogen Corporation N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands
US5756518A (en) 1996-04-02 1998-05-26 Kowa Co., Ltd. Phenylene derivatives
JPH1029979A (ja) 1996-04-12 1998-02-03 Ajinomoto Co Inc 新規ピリジン誘導体
US5741798A (en) 1996-06-03 1998-04-21 Boehringer Ingelheim Pharmaceuticals, Inc. 2-benzyl-4-sulfonyl-4H-isoquinolin-1,3-diones and their use as antiinflammatory agents
AU3783497A (en) 1996-08-09 1998-03-06 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
PL331599A1 (en) 1996-08-14 1999-08-02 Zeneca Ltd Substituted derivatives of pyrimidine and their pharmaceutical application
JP2001502300A (ja) 1996-09-16 2001-02-20 デュポン ファーマシューティカルズ カンパニー ピラジノン類およびトリアジノン類およびその誘導体類
DE19638486A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
DE19638484A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
WO1998024780A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidinone and pyridinone compounds and their use
DE69812934T2 (de) 1997-01-24 2004-01-29 Conpharma As Oslo Gemcitabin-derivate
US5855654A (en) 1997-01-30 1999-01-05 Rohm And Haas Company Pyridazinones as marine antifouling agents
FR2759366B1 (fr) 1997-02-11 1999-04-16 Centre Nat Rech Scient Composes constituant notamment des effecteurs de recepteurs du systeme nerveux central sensibles aux amino acides neuroexcitateurs, leur preparation et leurs applications biologiques
US6262068B1 (en) 1997-02-21 2001-07-17 Bristol-Myers Squibb Company Lactam derivatives as antiarrhythmic agents
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
ES2131463B1 (es) 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
GB9708945D0 (en) 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
AU743899B2 (en) 1997-07-18 2002-02-07 Georgetown University Bicyclic metabotropic glutamate receptor ligands
DK0891978T3 (da) 1997-07-18 2002-07-01 Hoffmann La Roche 5H-Thiazol(3,2-a)pyrimidinderivativer
EP1035848B1 (en) 1997-07-31 2003-04-23 Celgene Corporation Substituted alkanohydroxamic acids and method of reducing tnf-alpha levels
AU741532B2 (en) 1997-08-14 2001-12-06 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
US6358975B1 (en) 1997-08-15 2002-03-19 Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6121278A (en) 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU9740998A (en) 1997-09-08 1999-03-29 F. Hoffmann-La Roche Ag Piperidine derivatives against malaria
ES2200248T3 (es) 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1019391A1 (en) 1997-10-02 2000-07-19 Merck & Co. Inc. Inhibitors of prenyl-protein transferase
WO1999019301A1 (fr) 1997-10-14 1999-04-22 Yoshitomi Pharmaceutical Industries, Ltd. Composes de piperazine et utilisation medicale desdits composes
WO1999021992A2 (en) 1997-10-23 1999-05-06 Ganimed Pharmaceuticals Gmbh Nucleic acid molecules encoding a glutamate receptor
WO1999031062A1 (fr) 1997-12-17 1999-06-24 Shionogi & Co., Ltd. Nouveaux composes de pyridine
US6054470A (en) 1997-12-18 2000-04-25 Boehringer Ingelheim Pharmaceuticals, Inc. Src family SH2 domain inhibitors
US6013672A (en) 1997-12-18 2000-01-11 Uab Research Foundation Agonists of metabotropic glutamate receptors and uses thereof
KR20010033241A (ko) 1997-12-19 2001-04-25 스티븐 엠. 오드레 치환된 피리딘 및 피리다진 화합물과 그것의 제약학적 용도
FR2772763B1 (fr) 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
IT1298155B1 (it) 1998-01-19 1999-12-20 Moreno Paolini Composti pirimidin 3-ossido per il trattamento delle patologie muscolo-scheletriche, in particolare per il trattamento della
US6664250B2 (en) 1998-01-20 2003-12-16 Bristol-Myers Squibb Co. Lactam derivatives as antiarrhythmic agents
ES2191412T3 (es) 1998-01-28 2003-09-01 Taisho Pharmaceutical Co Ltd Derivados de aminoacidos que contienen fluor.
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
PL343278A1 (en) 1998-03-17 2001-08-13 Pfizer Prod Inc Bicyclo[2.2.1]heptanes and related compounds
CN1295570A (zh) 1998-04-08 2001-05-16 诺瓦提斯公司 N－吡啶酮基除草剂
AU3170099A (en) 1998-04-16 1999-11-08 Yamanouchi Pharmaceutical Co., Ltd. Remedies for obesity
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
DE19822198C2 (de) 1998-05-16 2003-02-13 Wella Ag Oxonolfarbstoffe enthaltende Mittel und Verfahren zur Erzeugung von semipermanenten Färbungen auf Haaren
BR9910864A (pt) 1998-06-04 2002-02-05 Abbott Lab Compostos anti-inflamatórios para inibição de aderência celular
DE19826671A1 (de) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
FR2781218B1 (fr) 1998-07-15 2001-09-07 Lafon Labor Compositions pharmaceutiques comprenant des 2-quinolones
JP2000072751A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
CA2341409A1 (en) 1998-08-31 2000-03-09 Merck And Co., Inc. Novel angiogenesis inhibitors
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物
WO2000012464A1 (fr) 1998-08-31 2000-03-09 Taisho Pharmaceutical Co., Ltd. Derives de 6-fluorobicyclo[3. 1.0]hexane
CH694053A5 (de) 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
US6284759B1 (en) 1998-09-30 2001-09-04 Neurogen Corporation 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands
SE9803518D0 (sv) 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
PE20001236A1 (es) 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
US6133271A (en) 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US5948911A (en) 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
EP1006112A1 (en) 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers
RU2240998C2 (ru) 1998-12-04 2004-11-27 Бристол-Маерс Сквибб Компани Производные 3-замещенного 4-арилхинолин-2-она в качестве модуляторов калиевых каналов
WO2000044277A2 (en) 1999-02-01 2000-08-03 A.C.Cossor & Son (Surgical) Limited Improvements in or relating to sphygmomanometers and other devices
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
TW564247B (en) 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
GB9908175D0 (en) 1999-04-09 1999-06-02 Lilly Co Eli Method of treating neurological disorders
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
AU4797400A (en) 1999-05-17 2000-12-05 Eli Lilly And Company Metabotropic glutamate receptor antagonists
EP1595871A3 (en) 1999-06-02 2005-11-30 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
CA2390948A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6498180B1 (en) 1999-06-03 2002-12-24 Eli Lilly And Company Excitatory amino acid receptor modulators
JP4783967B2 (ja) 1999-07-21 2011-09-28 大正製薬株式会社 含フッ素アミノ酸誘導体を有効成分とする医薬
MXPA02001340A (es) 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
DE60006618T2 (de) * 1999-08-06 2004-09-23 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7040838B2 (en) 1999-08-27 2006-05-09 Kristar Enterprises, Inc. High capacity catch basin filtration system with adjustable deflector ring
SI1224174T1 (en) 1999-10-15 2003-12-31 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
CN1199954C (zh) 1999-10-15 2005-05-04 弗·哈夫曼-拉罗切有限公司 苯并二氮杂䓬衍生物
CZ20021390A3 (cs) 1999-10-19 2002-09-11 Merck & Co., Inc. Inhibitory tyrosinkinázy
EP1230225A2 (en) 1999-11-01 2002-08-14 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
GB2355982A (en) 1999-11-03 2001-05-09 Lilly Co Eli Heterocyclic amino acids
WO2001046190A1 (fr) 1999-12-22 2001-06-28 Kyorin Pharmaceutical Co., Ltd. Composes tricycliques et sels d'addition de ceux-ci
BR0107732A (pt) 2000-01-20 2003-03-11 Eisai Ltd Método para prevenir ou tratar uma doença
GB0002100D0 (en) 2000-01-28 2000-03-22 Novartis Ag Organic compounds
AU2001234420A1 (en) 2000-02-03 2001-08-14 Eli Lilly And Company Potentiators of glutamate receptors
EP1261327B1 (en) 2000-02-25 2005-04-27 F.Hoffmann-La Roche Ag Adenosine receptor modulators
DE10012373A1 (de) 2000-03-14 2001-09-20 Dresden Arzneimittel Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion
GB0007108D0 (en) 2000-03-23 2000-05-17 Novartis Ag Organic compounds
US6469026B2 (en) 2000-03-24 2002-10-22 Millennium Pharmaceuticals, Inc. Isoquinolone inhibitors of factor Xa
GB0007193D0 (en) 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
EP1277754B8 (en) 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridine derivatives
WO2001083431A1 (fr) 2000-04-28 2001-11-08 Shionogi & Co., Ltd. Inhibiteurs de mmp-12
CZ301809B6 (cs) 2000-04-28 2010-06-30 Nihon Nohyaku Co., Ltd. Zpusob prípravy 2-halogenbenzoových kyselin a jejich derivátu
US20020009713A1 (en) 2000-05-11 2002-01-24 Miller Freda D. Methods for identifying modulators of neuronal growth
AU2001256039A1 (en) 2000-05-11 2001-11-20 Kenneth Curry Novel spiro(2.4)heptane amino carboxy compounds and derivatives thereof
WO2001085716A1 (en) 2000-05-11 2001-11-15 Kyowa Hakko Kogyo Co., Ltd 2-piperidone compounds for the treatment of cancer
US7081481B2 (en) 2000-05-31 2006-07-25 Eli Lilly And Company Excitatory amino acid receptor modulators
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
US6962976B2 (en) 2000-06-27 2005-11-08 Centre National De La Recherche Scientifique-Cnrs Human TREK2, a stretch- and arachidonic acid-sensitive K+ channel activated by inhalational anesthetics and niluzole
JP2002003401A (ja) 2000-06-27 2002-01-09 Japan Science & Technology Corp 脳由来神経栄養因子誘導剤
JP2002012533A (ja) 2000-06-27 2002-01-15 Kao Corp 染毛剤組成物
CA2411059A1 (en) 2000-06-28 2002-12-06 Taisho Pharmaceutical Co., Ltd. Novel dicarboxylic acid derivatives
DE10031390A1 (de) 2000-07-03 2002-01-17 Knoll Ag Pyrimidinderivate und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
JP2002069057A (ja) 2000-07-07 2002-03-08 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
JP2002040252A (ja) 2000-07-27 2002-02-06 Shiseido Co Ltd コレステリック液晶層を含む光学シート、それを用いた情報記録体、情報記録方法並びに情報判別方法
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
KR100804111B1 (ko) 2000-08-11 2008-02-18 에자이 알앤드디 매니지먼트 가부시키가이샤 2-아미노피리딘 화합물 및 그의 의약 용도
KR100732206B1 (ko) 2000-09-11 2007-06-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
US6599940B2 (en) 2000-09-13 2003-07-29 Georgetown University Synthesis of 2-hydroxymethylglutamic acid and congeners thereof
JP2002105085A (ja) 2000-09-28 2002-04-10 Yamanouchi Pharmaceut Co Ltd 新規イミダゾチアゾール誘導体
CN1703403A (zh) 2000-10-02 2005-11-30 詹森药业有限公司 趋代谢的谷氨酸盐受体拮抗剂
DE10058663A1 (de) 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
JPWO2002051849A1 (ja) 2000-12-26 2004-04-22 第一製薬株式会社 Ｃｄｋ４活性阻害剤
JP2002308882A (ja) 2001-02-08 2002-10-23 Yamanouchi Pharmaceut Co Ltd チエノピリミジン誘導体
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
ES2360205T3 (es) 2001-03-02 2011-06-01 Agennix Ag Sistema de ensayo de tres híbridos.
AU2002308354A1 (en) 2001-03-08 2002-09-24 Ilfa Industrieelektronik Und Leiterplattenfertigung Aller Art Gmbh Multilayer printed circuit board
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
CA2443144A1 (en) 2001-04-02 2002-10-10 Merck & Co., Inc. In vivo methods of determining activity of receptor-type kinase inhibitors
DE60205100T2 (de) 2001-04-12 2006-06-01 F. Hoffmann-La Roche Ag DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN
CZ20033002A3 (cs) 2001-04-12 2004-03-17 F. Hoffmann-La Roche Ag Deriváty dihydrobenzo [b] [1,4]diazepin-2-onu jako antagonisty mGluR2
SE0101579D0 (sv) 2001-05-04 2001-05-04 Astrazeneca Ab New compounds
HUP0304048A2 (hu) 2001-05-14 2004-04-28 Bristol-Myers Squibb Pharma Company Szubsztituált pirazinon-, piridin- és pirimidinszármazékok és alkalmazásuk kortikotropin-felszabadító faktor ligandumokként és ezeket tartalmazó gyógyszerkészítmények
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
EP1406611A2 (en) 2001-05-30 2004-04-14 Alteon, Inc. Method for treating fibrotic diseases or other indications
CA2448317A1 (en) 2001-05-30 2002-12-05 Alteon Inc. Method for treating glaucoma v
ATE338035T1 (de) 2001-06-05 2006-09-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen
EP1408042A4 (en) 2001-06-14 2005-02-02 Banyu Pharma Co Ltd NOVEL ISOXAZOLOPYRIDONE DERIVATIVES AND THEIR USE
EP1397142A4 (en) 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
JP2003012653A (ja) 2001-06-28 2003-01-15 Yamanouchi Pharmaceut Co Ltd キナゾリン誘導体
AU2002321878A1 (en) 2001-08-02 2003-02-17 Neurocrine Biosciences, Inc. Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
EP1425284A2 (en) 2001-09-11 2004-06-09 Smithkline Beecham Corporation Furo- and thienopyrimidine derivatives as angiogenesis inhibitors
ATE403657T1 (de) 2001-10-02 2008-08-15 Smithkline Beecham Corp Chemische verbindungen
TWI330183B (es) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
TW200406466A (en) 2001-11-13 2004-05-01 Ciba Sc Holding Ag Compositions comprising at least one oxonol dye and at least one metal complex
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
EP1458374A2 (en) 2001-12-14 2004-09-22 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
ES2311642T3 (es) 2001-12-27 2009-02-16 Taisho Pharmaceutical Co., Ltd Derivados de 6-fluorobicicli 3.1.0 hexano.
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
WO2003062192A1 (en) 2002-01-17 2003-07-31 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
WO2003062392A2 (en) 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
WO2003064428A1 (en) 2002-01-29 2003-08-07 H. Lundbeck A/S Furano- and thienopyrimidines as neurokinase inhibitors
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
WO2003065994A2 (en) 2002-02-07 2003-08-14 University Of Miami Schwann cell and phosphodiesterase inhibitors based therapy
US20040116489A1 (en) 2002-02-12 2004-06-17 Massey Steven Marc Synthetic excitatory amino acids
EP1484320A1 (en) 2002-02-13 2004-12-08 Takeda Chemical Industries, Ltd. Jnk inhibitor
BR0307631A (pt) 2002-02-14 2004-12-21 Pharmacia Corp Piridinonas substituìdas como moduladores de p38 map-quinase
AU2003205558A1 (en) 2002-02-19 2003-09-09 H. Lundbeck A/S Thioibotenic acid and derivatives thereof
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
AU2003223953A1 (en) 2002-03-14 2003-09-22 Bayer Healthcare Ag Monocyclic aroylpyridinones as antiinflammatory agents
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
KR101061561B1 (ko) 2002-03-29 2011-09-02 얀센 파마슈티카 엔.브이. 대사자극성 글루타메이트 수용체 리간드로서 방사능표지된 퀴놀린 및 퀴놀리논 유도체 및 그의 용도
EP1492595A1 (en) 2002-04-03 2005-01-05 Eli Lilly And Company Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
DE60318198T2 (de) 2002-05-02 2008-12-04 Merck & Co., Inc. Tyrosinkinase-hemmer
US6864261B2 (en) 2002-05-02 2005-03-08 Euro-Celtique S.A. Therapeutic agents useful for treating pain
AU2003234628B2 (en) 2002-05-21 2007-08-23 Amgen Inc. Substituted heterocyclic compounds and methods of use
EA014979B1 (ru) 2002-06-11 2011-04-29 Эли Лилли Энд Компани Пролекарства возбуждающих аминокислот
US7727992B2 (en) 2002-06-13 2010-06-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2003246927A1 (en) 2002-07-03 2004-01-23 Astex Technology Limited 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
GB0218800D0 (en) 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
WO2004018386A2 (en) * 2002-08-26 2004-03-04 Merck & Co., Inc. Acetophenone potentiators of metabotropic glutamate receptors
WO2004019863A2 (en) 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
ES2381664T3 (es) 2002-09-10 2012-05-30 Novartis Ag Combinaciones de antagonistas del receptor metabotrópico de glutamato y su uso en el tratamiento de trastornos adictivos
EP1546201A4 (en) 2002-09-11 2006-08-16 Merck & Co Inc NUCLEIC ACID SEQUENCES CODING TO MGLUR2 AND MGLUR3 FOR NEW POINT MUTATIONS
WO2004026875A1 (en) 2002-09-19 2004-04-01 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors
ATE331716T1 (de) 2002-09-19 2006-07-15 Boehringer Ingelheim Ca Ltd Nicht-nukleosidische inhibitoren der reverse transkriptase
AR044743A1 (es) 2002-09-26 2005-10-05 Nihon Nohyaku Co Ltd Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos,
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
US7998163B2 (en) 2002-10-03 2011-08-16 Boston Scientific Scimed, Inc. Expandable retrieval device
ATE450619T1 (de) 2002-10-23 2009-12-15 Daiichi Pure Chemicals Co Ltd Defructosylierungsverfahren
US20040138204A1 (en) 2002-10-30 2004-07-15 Harrington James Frederick Compositions and methods for pain reduction
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
EP2361913A1 (en) 2002-11-01 2011-08-31 Abbott Laboratories Anti-infective agents
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
ES2375111T3 (es) 2002-11-21 2012-02-24 Novartis Ag Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-quinasa y su uso en el tratamiento de c�?ncer.
WO2004054979A1 (ja) 2002-12-18 2004-07-01 Takeda Pharmaceutical Company Limited Ｊｎｋ阻害剤
BR0317714A (pt) * 2002-12-23 2005-11-22 Hoffmann La Roche Oxazóis como realçadores de mglur1
DE60330187D1 (de) 2002-12-30 2009-12-31 Celgene Corp Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
BRPI0406761A (pt) 2003-01-14 2005-12-20 Arena Pharm Inc Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
ITMI20030151A1 (it) 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
WO2004069826A1 (en) 2003-02-04 2004-08-19 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2515963A1 (en) 2003-02-24 2004-09-10 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
ES2297386T3 (es) 2003-03-03 2008-05-01 F. Hoffmann-La Roche Ag Tetrahidroisoquinolinas 2,5-sustituidas para uso como moduladores de 5-ht6.
ITFI20030058A1 (it) 2003-03-06 2004-09-07 Univ Firenze Formulazioni farmaceutiche contenenti tiazolidinedioni
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
CA2517161C (en) 2003-03-13 2011-08-16 T. Rad Co., Ltd. Steam reformer
WO2004092123A2 (en) 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
JP2006523707A (ja) 2003-04-15 2006-10-19 アストラゼネカ アクツィエボラーグ 治療化合物
JP2004339080A (ja) 2003-05-13 2004-12-02 Tokyo Institute Of Technology ピラゾ−ル誘導体を含有する高血圧治療剤
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
US20070053831A1 (en) 2003-05-20 2007-03-08 Barrio Jorge R Methods for binding agents to b-amyloid plaques
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1680125A1 (en) 2003-07-02 2006-07-19 Warner-Lambert Company LLC Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
CA2532203A1 (en) 2003-07-14 2005-01-27 Decode Genetics Ehf. Method of diagnosis and treatment for asthma based on haplotype association
GB0320300D0 (en) 2003-08-29 2003-10-01 Cancer Rec Tech Ltd Pyrimidothiophene compounds
AU2004268820B2 (en) 2003-08-29 2011-07-21 Cancer Research Technology Ltd Pyrimidothiophene compounds
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
MXPA06009019A (es) * 2004-02-18 2007-03-08 Astrazeneca Ab Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotropico.
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
AU2005233437A1 (en) 2004-04-12 2005-10-27 Sankyo Company, Limited Thienopyridine derivatives
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
US8063004B2 (en) 2004-07-22 2011-11-22 Malcera, L.L.C. Chemical composition of matter for the liquefaction and dissolution of asphaltene and paraffin sludges into petroleum crude oils and refined products at ambient temperatures and method of use
WO2006015158A1 (en) 2004-07-30 2006-02-09 Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors
CN1993326A (zh) * 2004-07-30 2007-07-04 默克公司 代谢型谷氨酸受体的杂环苯乙酮增效剂
ATE390424T1 (de) 2004-08-02 2008-04-15 Sanol Arznei Schwarz Gmbh Carboxamide des indolizins und seiner aza- und diazaderivate
EP1778093B1 (en) 2004-08-11 2013-04-03 Koninklijke Philips Electronics N.V. Ultrasonic diagnosis of ischemic cardiodisease
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
JP2008509985A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー 炎症治療用の新規トリアゾロピリジン化合物
DE102004044884A1 (de) 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20080096935A1 (en) 2004-10-25 2008-04-24 Pinkerton Anthony B Heterocyclic Indanone Potentiators of Metabotropic Glutamate Receptors
JP5184089B2 (ja) 2004-11-22 2013-04-17 イーライ リリー アンド カンパニー グルタミン酸受容体の増強剤
US7434262B2 (en) 2004-12-08 2008-10-07 At&T Intellectual Property I, L.P. Methods and systems that selectively resurrect blocked communications between devices
DE102004061288A1 (de) 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
CA2591003A1 (en) 2004-12-27 2006-07-06 Astrazeneca Ab Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
EP1855670A4 (en) 2005-02-24 2010-05-05 Merck Sharp & Dohme BENZAZOLE POTENTIALIZERS OF METABOTROPIC GLUTAMATE RECEPTORS
EP1863818B1 (en) 2005-03-23 2010-03-10 F.Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
WO2006109876A1 (ja) 2005-04-08 2006-10-19 Eisai R & D Management Co., Ltd. 不随意運動治療剤
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2006137350A1 (ja) 2005-06-22 2006-12-28 Kissei Pharmaceutical Co., Ltd. 新規なフロピリジン誘導体、それを含有する医薬組成物およびそれらの用途
US20070032469A1 (en) 2005-08-05 2007-02-08 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
WO2007021308A1 (en) 2005-08-12 2007-02-22 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
WO2007027669A1 (en) 2005-08-29 2007-03-08 Cps Biofuels, Inc. Improved biodiesel fuel, additives, and lubbricants
BRPI0617166A2 (pt) 2005-09-17 2011-07-12 Speedel Experimenta Ag derivados de 5-amino-4-hidróxi-7-(imidazo[1,2-a]piridin-6-ilmetil)-8-me til-nonamidia e compostos relacionados como inibidores de renina para o tratamento de hipertensão
EP1764099A3 (en) 2005-09-17 2007-05-09 Speedel Experimenta AG Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV
WO2008051197A2 (en) 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
CN101273040B (zh) 2005-09-27 2011-11-09 弗·哈夫曼-拉罗切有限公司 作为mglur2拮抗剂的*二唑基吡唑并嘧啶类化合物
EP1971601B1 (en) 2005-11-15 2009-10-21 Array Biopharma Inc. N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
TW200732313A (en) 2005-12-15 2007-09-01 Astrazeneca Ab Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
US20090203732A1 (en) 2006-03-02 2009-08-13 Dashyant Dhanak Thiazolones for Use as P13 Kinase Inhibitors
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
WO2007135527A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
WO2007135529A2 (en) 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
EP2039687B1 (en) 2006-06-19 2012-05-02 Toray Industries, Inc. Therapeutic or prophylactic agent for multiple sclerosis
EP2046788A1 (en) 2006-07-12 2009-04-15 Syngeta Participations AG Triazolopyridine derivatives as herbicides
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
WO2008012622A2 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Azabenzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2008012623A1 (en) 2006-07-25 2008-01-31 Pfizer Products Inc. Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor
WO2008032191A2 (en) 2006-09-13 2008-03-20 Astrazeneca Ab Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
CA2665195C (en) 2006-10-11 2011-08-09 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use thereof
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
MX2009006704A (es) 2006-12-22 2009-06-30 Astex Therapeutics Ltd Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
AR064491A1 (es) 2006-12-22 2009-04-08 Astex Therapeutics Ltd Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr.
CN101605792A (zh) 2007-02-09 2009-12-16 阿斯利康(瑞典)有限公司 氮杂-异吲哚酮和它们作为亲代谢性谷氨酸受体增效剂-613的用途
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
NZ579372A (en) 2007-03-07 2012-02-24 Janssen Pharmaceutica Nv Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
KR20090128454A (ko) 2007-03-07 2009-12-15 얀센 파마슈티카 엔.브이. 에스트로겐 관련 수용체-알파 조절제로서 치환된 페녹시 아미노티아졸론
NZ579418A (en) 2007-03-07 2012-01-12 Janssen Pharmaceutica Nv Substituted phenoxy n-alkylated thiazolidinedione as estrogen related receptor-alpha modulators
TW200900391A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
CN104447792A (zh) 2007-03-09 2015-03-25 赛诺菲-安万特股份有限公司 取代的二氢和四氢噁唑并嘧啶酮及其制备和用途
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2008130853A1 (en) 2007-04-17 2008-10-30 Astrazeneca Ab Hydrazides and their use as metabotropic glutamate receptor potentiators - 681
ES2530431T3 (es) 2007-05-25 2015-03-02 Abbvie Deutschland Compuestos heterocíclicos como moduladores positivos del receptor de glutamato metabotrópico 2 (receptor mGlu2)
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
MX2010002537A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-fenil-1h-piridin-2-onas 1,3-disubstituidas.
ES2365966T3 (es) 2007-09-14 2011-10-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disustituidas.
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2244576A4 (en) 2008-01-24 2011-06-08 Merck Sharp & Dohme 1,3-OXAZOLIDIN-2-ONE 3,5-SUBSTITUTED DERIVATIVES
JP5309162B2 (ja) 2008-03-06 2013-10-09 サノフイ 置換されたジヒドロ、トリヒドロ及びテトラヒドロシクロアルキルオキサゾロピリミジノン、その製造及び使用
DE102008001056A1 (de) 2008-04-08 2009-10-15 Robert Bosch Gmbh Umlenkeinrichtung für einen Strahl einer elektromagnetischen Welle
CA2723727A1 (en) 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
US20110065669A1 (en) 2008-05-15 2011-03-17 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
US20100037487A1 (en) 2008-08-14 2010-02-18 Susan Connett Method and apparatus for sandal with hidden strap adjustment
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之***吡啶化合物
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
AT507619B1 (de) 2008-12-05 2011-11-15 Oesterreichisches Forschungs Und Pruefzentrum Arsenal Ges M B H Verfahren zur approximation des zeitlichen verlaufs von verkehrsdaten
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2010114726A1 (en) 2009-03-31 2010-10-07 Merck Sharp & Dohme Corp. Aminobenzotriazole derivatives
EP2417135A1 (en) 2009-04-07 2012-02-15 Schering Corporation Substituted triazolopyridines and analogs thereof
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011011964A (es) 2009-05-12 2012-02-23 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos.
AR076859A1 (es) 2009-05-12 2011-07-13 Ortho Mcneil Janssen Pharm Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
WO2010141360A1 (en) 2009-06-05 2010-12-09 Merck Sharp & Dohme Corp. Biaryl benzotriazole derivatives
WO2011022312A1 (en) 2009-08-20 2011-02-24 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
CN102002040A (zh) 2009-09-01 2011-04-06 上海药明康德新药开发有限公司 一种***并吡啶环化合物的合成方法
WO2011034741A1 (en) 2009-09-15 2011-03-24 Merck Sharp & Dohme Corp. Imidazopyridin-2-one derivatives
AR078172A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Fenoximetil dihidro oxazolopirimidinonas sustituidas y uso de las mismas como moduladores de receptores metabotropicos de mglur
AR078171A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparacion y uso de las mismas
AR078173A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Bifeniloximetil dihidro oxazolopirimidinonas sustituidas, su preparacion y su uso
JP5204071B2 (ja) 2009-09-25 2013-06-05 パナソニック株式会社 電気かみそり
EP2496569A2 (en) 2009-11-02 2012-09-12 MSD Oss B.V. Heterocyclic derivatives
JP2013521290A (ja) 2010-03-04 2013-06-10 メルク・シャープ・エンド・ドーム・コーポレイション Ｍｇｌｕｒ２の正のアロステリックモジュレータ
WO2011116356A2 (en) 2010-03-19 2011-09-22 Sanford-Burnham Medical Research Institute Positive allosteric modulators of group ii mglurs
US8664214B2 (en) 2010-03-30 2014-03-04 AbbVie Deutschland GmbH & Co. KG Small molecule potentiators of metabotropic glutamate receptors I
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
US20130035332A1 (en) 2010-04-29 2013-02-07 Layton Mark E Substituted 1,3-Benzothiazol-2(3H)-Ones and [1,3]Thiazolo[5,4-B]Pyridin-2(IH)-Ones as Positive Allosteric Modulators of MGLUR2
BR112012027628A2 (pt) 2010-04-30 2016-08-09 Astrazeneca Ab polimorfos de um modulador alostérico positivo de receptor de glutamato metabotrópico
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
CN101893589B (zh) 2010-06-29 2012-10-17 中国人民解放军第三0二医院 一种无菌检查方法及其使用的全封闭集菌安瓿培养器
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
US8785481B2 (en) 2010-09-29 2014-07-22 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20130230459A1 (en) 2010-11-08 2013-09-05 Janssen Pharmaceuticals, Inc. RADIOLABELLED mGluR2 PET LIGANDS
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-***并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
EP2705025A4 (en) 2011-05-03 2015-01-21 Merck Sharp & Dohme Hydroxymethyl-biaryl BENZOTRIAZOL DERIVATIVES
WO2012151139A1 (en) 2011-05-03 2012-11-08 Merck Sharp & Dohme Corp. Alkyne benzotriazole derivatives
EP2704573A4 (en) 2011-05-03 2014-10-15 Merck Sharp & Dohme AMINOMETHYL biaryl BENZOTRIAZOL DERIVATIVES

Also Published As

Publication number Publication date
JP2010520265A (ja) 2010-06-10
US8906939B2 (en) 2014-12-09
AU2008223796A1 (en) 2008-09-12
IL200329A0 (en) 2010-04-29
US20100087487A1 (en) 2010-04-08
EA200901160A1 (ru) 2010-04-30
EA017294B1 (ru) 2012-11-30
TW200845978A (en) 2008-12-01
JP5357061B2 (ja) 2013-12-04
WO2008107481A8 (en) 2008-12-24
CN101711244A (zh) 2010-05-19
EP2134708A1 (en) 2009-12-23
NZ579988A (en) 2011-09-30
KR20090125814A (ko) 2009-12-07
AR065654A1 (es) 2009-06-24
EP2134708B1 (en) 2011-05-11
CA2680104A1 (en) 2008-09-12
AU2008223796B2 (en) 2011-03-17
CN101711244B (zh) 2013-01-16
PL2134708T3 (pl) 2011-10-31
BRPI0808509A2 (pt) 2014-08-19
WO2008107481A1 (en) 2008-09-12
CA2680104C (en) 2016-05-31
ATE509020T1 (de) 2011-05-15
DK2134708T3 (da) 2011-08-29

Similar Documents

Publication Publication Date Title
MX2009009424A (es) Derivados de 3-ciano-4-(4-tetrahidropiran-fenil)-piridin-2-ona.
MX2009009423A (es) Derivados de 3-ciano-4-(4-fenil-piperidin-1-il)-piridin-2-ona.
MX2009009422A (es) Derivados de 3-ciano-piridona 1,4-disustituidos y su uso como moduladores del receptor mglur-2 positivo.
EA017914B8 (ru) 1,4-ДВУЗАМЕЩЕННЫЕ 3-ЦИАНОПИРИДОНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЗИТИВНЫХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
MX2010002537A (es) 4-fenil-1h-piridin-2-onas 1,3-disubstituidas.
TW200633982A (en) Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
MX2010002538A (es) 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas.
MX2010002536A (es) 4-fenil-3,4,5,6-tetrahidro-2h, 1'h-[1,4]bipiridinil-2'-onas 1',3'-disubstituidas.
MX2011003691A (es) Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
MX2010005110A (es) Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
MY153912A (en) 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JO2907B1 (en) Pyridine derivatives 1, 2, 4 trisolo [4, 3-A] and their uses as positive LLs for 2MGLUR receptors
TW200634016A (en) Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors
MX2011011963A (es) Derivados de 7-aril-1,2,4-triazolo[4,3-a]piridina y uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
MX2011005242A (es) Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
WO2011051490A3 (en) Heterocyclic derivatives
MX2012007005A (es) Tiazoles biciclicos como moduladores alostericos de recptores de glutamato metabotropico subtipo 5.
IN2012DN03322A (es)
MX2012007006A (es) Tiazoles biciclicos como moduladores alostericos de receptores mglur5.
UA99123C2 (en) 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives

Legal Events

Date Code Title Description
FG Grant or registration